Enzymatica focuses on product development based on the tested and patented barrier technology used in the cold product ColdZyme. Strengthening the clinical documentation for ColdZyme is a key part of Enzymatica’s R&D activities.
Enzymatica wants to be a good stakeholder in the community and take responsibility for sustainable social development.
As a medical device company, Enzymatica focuses on human health and well-being, and wants to use resources, regardless of whether they are raw materials, energy or human, as wisely and sustainably as possible.
Regarding basic research, production and sales of products, the Company cooperates to a large extent with partners, many of whom actively work with sustainability issues.
ColdZyme reduces the risk of catching a cold and shortens the duration of illness at an early stage of infection.
Extensive market and strong presence on the home market
Enzymatica operates on a large market, colds, with strong underlying growth. The market for over-the-counter cold products amounted to USD 21.5 billion in 2017. Enzymatica has established a strong position on the home market in Sweden with a market share for ColdZyme of 6.5%, based on rolling 12-month data at year-end 2019/2020.
We are also building a strong distributor network. In 2019 the company signed agreement with partners for a new mouth spray for the German market, and in addition agreements of enzyme formulations for the German and Chinese markets. In the beginning of 2020 Enzymatica entered into an agreement regarding ColdZyme for the Chinese market.